One of the most skilled storytellers in the broadcast industry, Award-winning journalist John Seigenthaler recently joined Finn Partners. He is well known as a journalist for NBC, as anchor of NBC Nightly News Weekend Edition and Special Correspondent news anchor and has appeared on many news media, including Meet the Press, TODAY, Dateline, MSNBC, and CNBC.
During his career, Seigenthaler covered a wide range of major international and national stories, including U.S. Presidential campaigns, conventions, and breaking news in areas around the globe. Seigenthaler brings his expertise to Finn Partners to focus on national media story development, crisis communications, and reputation management counsel and will emphasize message development media direction/training, video, and social media strategy. He will be based in Finn Partners’ New York office.
Regeneron Adds Bonnie L. Bassler, PhD as Board Member
Regeneron Pharmaceuticals welcomes Bonnie L. Bassler, PhD to its Board of Directors. The accomplished scientist has earned various scientific honors including the MacArthur Foundation Fellowship and the Shaw Prize in Life Science and Medicine.
“Regeneron continues to maintain a Board of Directors primarily composed of accomplished scientists who provide critical input to the company’s scientific, technological and clinical strategy,” said Chairman, Dr. P. Roy Vagelos. “Bonnie’s lifelong work as a molecular biologist will strengthen Regeneron’s scientific approach.”
Bassler is currently the Chair of the Department of Molecular Biology and the Squibb Professor in Molecular Biology at Princeton University. Her studies are focused on the bacterial cell-to-cell communication and behavior. Bassler attained her PhD in Biochemistry from Johns Hopkins University.
Welcomes Daniel D. Von Hoff, MD, to its scientist advisory board. Hoff is Physician-in-Chief and distinguished professor at the Translational Genomics Research Institute. He has published more than 648 papers, earning him the David A. Karnofsky Memorial Award in 2010. He also served in President Bush’s National Cancer Advisory Board from 2004 to 2010.
Appoints Agatha Newman as an Associate Director. In her new role, she will serve as internal communication support to the Medical & Development team. Newman graduated from Saint Louis University magna cum laude, earning her bachelor’s degree in communication and a certificate in marketing. Her most recent role was at AbbVie.
Avedro, Inc. named Reza Zadno, PhD, as the company’s Chief Executive Officer. Zadno is widely recognized for his ophthalmology and life science sector expertise. The medical device expert and healthcare senior executive has served in leading companies including Visiogen where he was Founder, President and CEO.
Brings Phil Storer on board to reinforce the company’s “Perpetual Ideation Machine.” The digital strategist expert has accumulated 17 years of experience. Storer specializes in user experience in digital platforms, website construction, and visual aesthetics for the purpose of audience engagement and growth. He has launched interactive websites in more than 27 languages.
Giant Creative/Strategy, LLC
Promotes Kristina Ellis to Executive Vice President, Executive Creative Director. She has been with the company for nearly 13 years and has more than 17 years in the industry. She is now in charge of the San Francisco-based creative department, including all copy, art, and experience design functions.
Noven Pharmaceuticals Inc.
Adds Jeff Mihm to its Board of Directors. He is presently the company’s CEO. Previously, he served as the company’s VP, Chief Administrative Officer & General Counsel where he oversaw business development, corporate affairs, human resources, and more.
Names Dr. Frank Nestle as its Global Head of Immunology & Inflammation Research Therapeutic Area and also North America Chief Scientific Officer, based in Cambridge, Massachusetts. The company’s goal is to be in a leading position in areas of chronic inflammation and autoimmune disease. Nestle is a University of Wurzburg Medical School graduate, where he received his MD and became certified in dermatology, allergology and clinical immunology.
Names Todd Bazemore as Chief Operating Officer. The veteran has more than 22 years of experience in the industry, successfully launching and constructing brands, and has been a major factor in the advancement of various drugs in the therapeutic spectrum. Most recently he served as EVP & Chief Commercial Officer at Dyax Corp.
Sapience Therapeutics, Inc.
Announces Samuel Broder, MD, as a member of its Board of Directors. Dr. Broder’s career has dominantly focused on translational medicine. During the mid-1980s his research served as a major tool in the development of the first three FDA-approved agents to treat the AIDS virus. The former head of the National Cancer Institute has more than 35 years of experience in translating science from bench to bedside.
Tobira Therapeutics, Inc.
Appoints Laurent Fischer, MD, to its Liver Forum steering committee for which the company conjointly gather the necessary knowledge and expertise for the development of drugs geared toward treating liver disease. Dr. Fischer is currently the company’s CEO.
Names Arne von Bonin, PhD, as its Chief Scientific Officer. In his new role he will oversee the preclinical and early-phase development of the company’s projects. He received his PhD at the Max-Planck Institute for Immunobiology. Recently he served as CSO at Affiris, where his work was primarily based on vaccines targeting chronic immune disease.
Enlarged its advisory board, adding adjunct medicine professor Ronald N. Jones, MD. He teaches in Boston’s Tufts University School of Medicine. He is also the Founder and Chairman of JMI Laboratories in Iowa. He has written over 1,600 peer publications in topics of antimicrobial agents, antimicrobial susceptibility test development, and resistance mechanisms.